High-dose biotin trial produces disappointing results
This week, MedDay Pharmaceuticals announced that the second pivotal Phase 3 trial (SPI2) of MD1003 (biotin), an investigational product for primary and secondary progressive MS has failed to meet its primary and secondary endpoints.